States argue that biological samples, DNA data, health-related traits and medical records are too sensitive to be sold without each person's express, informed consent.

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent in ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...